Viking Therapeutics, Inc. (VKTX:NASDAQ) closed at $27.28 on October 30, 2026, up 1.56% on the day. The stock trades 36.8% below its 52-week high of $43.15 and 14.5% above its 52-week low of $23.82. Over the past year, it lost 28.4%. Viking Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 30, 2025, VKTX closed higher on 113 days (45%). Its best day was September 22, 2026 (+35.67%) and its worst was September 24, 2026 (-11.76%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Find more stocks like VKTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.